People · Operator
Named in public records as an officer, director or promoter · active 2016–2017 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Fate Therapeutics Inc | — | Biotechnology | Series C | $241.3M | $2.0B | 2016 |
| aTYR PHARMA INC | — | Biotechnology | Series C | $122.1M | $1.9B | 2017 |
TIMOTHY P. COUGHLIN at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside TIMOTHY P. COUGHLIN on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert Nelsen | 1 | 22 |
| Bryan Roberts | 1 | 18 |
| Michael Lee | 1 | 15 |
| Amir Nashat | 1 | 14 |
| Carl Weissman | 1 | 8 |
| James C. Blair | 1 | 8 |
| Robert Epstein | 1 | 8 |
| Bryan E. Roberts | 1 | 6 |
| PAUL Grayson | 1 | 5 |
| Robert T. Nelsen | 1 | 5 |
| John K. Clarke | 1 | 5 |
| William Rastetter | 1 | 4 |
| John Mendlein | 1 | 4 |
| AMIR S. NASHAT | 1 | 3 |
| ROBERT S. EPSTEIN | 1 | 3 |
| Robert Hershberg | 1 | 3 |
| Jeffrey S Hatfield | 1 | 2 |
| John T. Blake | 1 | 2 |
| Timothy Coughlin | 1 | 2 |
| William T. Rastetter | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.